Obesity & metabolic peptides

GLP-1 & obesity peptides: the complete class guide

This page groups every compound being developed or used for weight loss through the incretin and amylin hormone systems, whether it is a true GLP-1 receptor agonist, a dual or triple agonist, or an amylin analog with no GLP-1 activity at all. Some are FDA-approved; most are still in clinical trials. Each entry links to its own full write-up with dosage data, evidence tiers, and sources.

Ask PeptideBlog about any peptide

4 approved 26 compounds tracked Evidence-tiered
Why amylin analogs are grouped here too: Cagrilintide, petrelintide, and eloralintide do not touch the GLP-1 receptor at all. They work on the amylin receptor instead. They are included because they compete for the same clinical purpose (chronic weight management) and are frequently paired with or compared against true GLP-1 drugs in trials and in the research community. “GLP-1 class” is used loosely here the way it is used in practice: shorthand for the whole incretin-and-amylin obesity drug category, not a strict chemistry label.

Approved

Cleared by the FDA and in general clinical use.

CompoundMechanismStatusDeveloper / brand
SemaglutideGLP-1 receptor agonistApprovedNovo Nordisk (Ozempic, Wegovy)
TirzepatideGIP/GLP-1 dual agonistApprovedEli Lilly (Mounjaro, Zepbound)
LiraglutideGLP-1 receptor agonistApprovedNovo Nordisk (Victoza, Saxenda)
PramlintideAmylin analogApprovedApproved for diabetes (Symlin); amylin-class origin point
OrforglipronOral non-peptide GLP-1 agonistApprovedEli Lilly (Foundayo; US approval for chronic weight management, April 2026)

A recent Italian cohort study reported higher heart attack, stroke and death rates in time spent after stopping a GLP-1 drug. The GLP-1 discontinuation and mortality analysis covers why a hazard ratio of 4.81 is not a risk multiple.

Late-stage investigational

In Phase 2 or Phase 3 trials, or approved in one market and still investigational elsewhere.

CompoundMechanismStatusDeveloper
RetatrutideGIP/GLP-1/glucagon triple agonistPhase 3Eli Lilly
CagrilintideLong-acting amylin analogPhase 3Novo Nordisk (paired with semaglutide as CagriSema)
SurvodutideGLP-1/glucagon dual agonistPhase 3Boehringer Ingelheim / Zealand Pharma
MazdutideGLP-1/glucagon dual agonistPhase 3 / approved in ChinaInnovent Biologics / Eli Lilly
VK2735GIP/GLP-1 dual agonist (injectable and oral)Phase 3Viking Therapeutics
AmycretinGLP-1/amylin dual agonistPhase 2/3Novo Nordisk
PemvidutideGLP-1/glucagon dual agonistPhase 2Altimmune
Enicepatide (CT-388)GIP/GLP-1 dual agonistPhase 2Roche (via Carmot Therapeutics)
MariTide (maridebart cafraglutide)GIP/GLP-1 receptor bispecificPhase 3 (MARITIME program)Amgen
GSBR-1290 (aleniglipron)Oral non-peptide GLP-1 receptor agonistPhase 2bStructure Therapeutics
AZD5004 (elecoglipron)Oral non-peptide GLP-1 receptor agonistPhase 2 published, Phase 3 plannedAstraZeneca
RGT-075Oral non-peptide GLP-1 receptor agonistPhase 2bRegor Therapeutics
DanuglipronOral non-peptide GLP-1 receptor agonistDiscontinued (Apr. 2025, liver-injury signal)Pfizer
EloralintideAmylin analogPhase 3Eli Lilly

Early investigational

Earlier-phase candidates with limited public data so far.

CompoundMechanismStatusDeveloper
PetrelintideLong-acting amylin analogPhase 3Zealand Pharma
UBT251GIP/GLP-1/glucagon triple agonistEarly-to-mid phase (status disputed across sources)United Biotechnology
NisotirostideInvestigational incretin-class candidateEarly phaseNot yet disclosed
NBIP-1968Investigational incretin-class candidateEarly phaseNot yet disclosed
TERN-601Oral non-peptide GLP-1 receptor agonistPhase 2 (topline reported)Terns Pharmaceuticals
CT-996Oral non-peptide GLP-1 receptor agonistPhase 2, positive Phase 1Roche (via Carmot Therapeutics)
DapiglutideGLP-1/GLP-2 dual agonistPaused (positive Phase 1b, program paused for pipeline priorities)Zealand Pharma

Also see: brenipatide, a Lilly GIP/GLP-1 agonist in phase 3 for alcohol use disorder and depression rather than weight loss, the retatrutide entry for the triple-agonist data, and our write-up on LY4086940, an oral Lilly compound in two registered trials.

Related reading: not every obesity candidate is a peptide. See how strong the evidence is for TOFA, a non-peptide metabolic compound studied in mice, and what human data is still missing. Another non-peptide, CBL-514, is an injectable studied for local abdominal fat rather than weight loss, and the article covers what its trials did and did not measure.

The amylin side of the class has its own comparison: petrelintide, eloralintide and cagrilintide compared, including the ZUPREME trial results. For the amounts and schedules reported for petrelintide, see the petrelintide dosage guide.

Brand names in this class are still moving. Eli Lilly holds live US trademark applications for Retzoundi and Retkouro, both filed on April 23, 2024, and has not said which medicine, if any, they are meant for. Posts online link them to retatrutide, but the filings name no drug. Our Retzoundi and Retkouro write-up sets out what the records show and what they leave out.

This is a compilation of publicly available information for educational reference, not medical advice, and not a recommendation to use any of these compounds. Approval and trial status change frequently, so check each compound’s own entry for the most current sourced detail.

Foundayo (orforglipron) is the oral small-molecule option in this class. Its dose ladder and capsule-to-tablet map are tabled in the orforglipron dosage guide.

Reported amounts and schedules for the main compounds in this class are tabled in separate dosage guides: semaglutide dosage, tirzepatide dosage, retatrutide dosage and cagrilintide dosage. Each one keeps published trial amounts separate from figures circulating online and names the source. For how these and other peptides are treated in compounding, see the FDA peptide status guide.

For how a single oral GLP-1 headline number is built, and why it cannot be ranked against other trials, see what the CX11 11.5% weight loss figure measures.